MGX Metagenomi Therapeutics, Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

MGX — —
Key stats
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
113
List Date
2024-02-09
CIK
0001785279
Next Earnings
2026-11-10
EPS Forecast
($0.74) (2 est.)
Headquarters
Emeryville, CA
Homepage
https://metagenomi.co

Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide cur…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'24'25'26Avg
Jan---29.02%-7.78%-18.40%
Feb15.03%-18.33%-1.30%-1.53%
Mar-12.08%-26.88%-12.42%-17.13%
Apr-35.12%31.06%2.99%-0.36%
May-9.38%14.09%-2.16%0.85%
Jun-39.01%-15.91%-9.16%-21.36%
Jul-12.22%51.82%-2.06%12.51%
Aug-15.14%-22.67%-2.48%-13.43%
Sep-24.91%30.22%-9.40%-1.36%
Oct-4.83%6.28%-30.55%*-9.70%
Nov-1.90%-27.69%---14.79%
Dec73.56%1.25%--37.41%
Total-67.13%-36.60%-56.15%-53.29%
* Only 3 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.93
SMA 50: $1.08
SMA 200: $1.31
Current: $0.77
EMA 12: $0.86
EMA 26: $0.95
MACD: -0.0886 | Signal: -0.0100
BEARISH
ADX (14): 49.30
STRONG TREND
+DI: 7.11
−DI: 32.42

Momentum Oscillators

RSI (14): 23.74
OVERSOLD
Stoch %K: 10.85
Stoch %D: 14.40
Williams %R: -94.39

Volume & Volatility

BB Upper: $1.16
BB Lower: $0.70
NEUTRAL
OBV: 88,483,735
Vol SMA 20: 167,890
Vol ROC: 45.58%
ATR: $0.06
True Range: $0.07
HV 20: 66.4%
HV 30: 57.1%
HV 60: 44.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report: MGX

Executive Summary:

Overall Assessment: NEUTRAL (confidence level: 6/10)

Key Drivers and Primary Risks:

  1. Recent news headlines highlighting positive developments in Metagenomi Therapeutics' pipeline and technology advancements.
  2. Technical indicators suggesting a potential range-bound trading environment, with some bearish momentum signals.

Investment Thesis: MGX may continue to experience volatility as it navigates the development of its compact CRISPR nuclease technology and clinical trial progress. While news sentiment is generally positive, technical signals suggest a neutral-to-bearish bias.

Recent News Sentiment Impact: The recent news headlines have contributed to a generally positive sentiment, with all six articles highlighting positive developments in Metagenomi Therapeutics' pipeline and technology advancements.

Technical Analysis:

Trend Direction: Short-term (1-4 weeks): NEUTRAL Medium-term (1-3 months): RANGE-BOUND Long-term (3-12 months): UPTRENDING

Support/Resistance Levels: Key price levels:

  • Lower Bollinger Band: $1.15
  • Middle Line: $1.20
  • Upper Bollinger Band: $1.25
  • SMA 50: $1.22
  • SMA 200: $1.43

Momentum Signals:

  • RSI (14): 38.05 (neutral)
  • MACD: -0.02 / Signal: -0.00 / Histogram: -0.01 (bearish)

Volume Analysis: Volume trends:

  • Volume SMA 20: 152158.25
  • On-Balance Volume (OBV): 85793719.28
  • Volume Rate of Change: 39.06%

News & Sentiment Analysis:

Recent Headlines Summary: Positive news headlines highlight Metagenomi Therapeutics' pipeline and technology advancements.

Sentiment Assessment: Aggregate sentiment is POSITIVE, with all six recent articles contributing to this assessment.

Catalyst Identification: Upcoming scientific meetings and presentation of data highlighting advancements in next-generation genome editing technologies.

Market Narrative: News sentiment aligns with the technical signals, suggesting a neutral-to-bearish bias in the short term.

Risk & Volatility Assessment:

Risk Metrics: Beta: 1.57 (vs SPY) Alpha: -0.55 Correlation: 0.32

Stock Volatility: 0.63 Interpretation: High volatility - stock moves more than market

Options Market Signals: No options data available.

Downside Protection: Support levels:

  • Lower Bollinger Band: $1.15
  • Middle Line: $1.20
  • SMA 50: $1.22

Market Context & Positioning:

Sector Performance: Metagenomi Therapeutics is part of the Biotechnology sector, which has experienced moderate growth.

Institutional Activity: Volume patterns suggest institutional interest in MGX's stock.

Correlation Analysis: MGX moves relatively independently of the market (R-squared interpretation).

Relative Valuation: MGX is trading within its historical range, with no clear valuation signal.

Key Levels & Action Items:

Critical Price Levels: Support/resistance levels:

  • Lower Bollinger Band: $1.15
  • Middle Line: $1.20
  • Upper Bollinger Band: $1.25
  • SMA 50: $1.22
  • SMA 200: $1.43

Breakout/Breakdown Levels: No clear breakout or breakdown levels.

Time-Sensitive Catalysts: Upcoming scientific meetings and presentation of data highlighting advancements in next-generation genome editing technologies.

Risk Management: Stop-loss levels:

  • Lower Bollinger Band: $1.15
  • Middle Line: $1.20

Position sizing considerations:

  • Consider hedging strategies if the stock moves significantly away from support/resistance levels.

By analyzing MGX's technical indicators, news sentiment, and risk metrics, it appears that the stock may continue to experience volatility as it navigates the development of its compact CRISPR nuclease technology and clinical trial progress. While news sentiment is generally positive, technical signals suggest a neutral-to-bearish bias in the short term.

Generated
News
All MGX news →
Showing 1–10 of 50
Page 1 of 5
Earnings History
1 of 1 under expected move
Avg Expected Move
—
Avg Actual Move
0.83%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2026-08-11 unknown — 0.83% — Within

Earnings calendar: this week’s reports with expected vs actual moves →

MGX Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.4059
Alpha: -135.86%
Correlation: 0.3245
R-Squared: 10.5%
Stock Volatility: 55.2%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own MGX
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$883K
0.00%
#2370 of 3138-5.8%13F
Millennium Management Hedge fund
Izzy Englander
$136K
0.00%
#3567 of 3716-33.0%13F
Citadel Hedge fund
Ken Griffin
$21K
0.00%
#6166 of 6285+5.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

MGX Institutional Ownership (13F)

Latest filings — 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

48 filers8,021,014 shares$10.68M value
# Filer Shares Value % of Total % of Float Period
1 Vanguard Group Inc Custodian 1,270,246 $2.06M 19.27% — 2025-12-31
2 Sozo Ventures GP II, L.P. 581,577 $1.33M 12.47% — 2025-09-30
3 Vanguard Capital Management LLC 1,077,700 $1.28M 12.01% — 2026-06-30
4 RENAISSANCE TECHNOLOGIES LLC 742,400 $883.46K 8.27% — 2026-06-30
5 Catalio Capital Management, LP 528,993 $629.50K 5.90% — 2026-06-30
6 Two Sigma Investments, LP Custodian 513,701 $611.30K 5.73% — 2026-06-30
7 Peapod Lane Capital LLC 490,992 $520.45K 4.87% — 2026-09-30
8 BRIDGEWAY CAPITAL MANAGEMENT, LLC 400,300 $476.36K 4.46% — 2026-06-30
9 Wells Fargo & Company Custodian 379,508 $451.61K 4.23% — 2026-06-30
10 Geode Capital Management, LLC Custodian 288,665 $343.67K 3.22% — 2026-06-30
11 PURA VIDA INVESTMENTS, LLC 264,391 $314.62K 2.95% — 2026-06-30
12 BlackRock, Inc. Custodian 257,631 $306.58K 2.87% — 2026-06-30
13 Vanguard Fiduciary Trust Co 171,251 $203.79K 1.91% — 2026-06-30
14 JACOBS LEVY EQUITY MANAGEMENT, INC 160,000 $190.40K 1.78% — 2026-06-30
15 State Street Corp 119,850 $142.62K 1.34% — 2026-06-30
16 Millennium Management LLC Custodian 114,025 $135.69K 1.27% — 2026-06-30
17 Man Group plc 109,130 $129.87K 1.22% — 2026-06-30
18 Resolute Advisors LLC 89,944 $107.03K 1.00% — 2026-06-30
19 Northern Trust Corp Custodian 68,938 $82.04K 0.77% — 2026-06-30
20 RBF Capital, LLC 64,021 $76.19K 0.71% — 2026-06-30
21 XTX Topco Ltd 55,707 $66.29K 0.62% — 2026-06-30
22 BBR PARTNERS, LLC 53,403 $63.55K 0.60% — 2026-06-30
23 Jane Street Group, LLC Custodian 38,396 $45.69K 0.43% — 2026-06-30
24 Fortitude Advisory Group L.L.C. 37,290 $39.53K 0.37% — 2026-09-30
25 Citadel Advisors LLC Custodian 17,851 $21.24K 0.20% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

MGX Insider Trading (Form 4)

Latest: 2026-09-11
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-11 Laurence Reid Director Buy (P) +20,000 $1.17 $23.4K EDGAR
2026-09-10 Pamela Wapnick Chief Financial Officer Sell (S) −1,911 $1.16 -$2.2K EDGAR
2026-09-10 Matthew Wein See Remarks Sell (S) −358 $1.16 -$415 EDGAR
2026-09-10 Jian Irish See Remarks Sell (S) −2,140 $1.16 -$2.5K EDGAR
2026-06-11 Eric Bjerkholt Director Grant (A) +21,000 opt — EDGAR
2026-06-11 Laurence Reid Director Grant (A) +17,400 opt — EDGAR
2026-06-11 Willard H Dere Director Grant (A) +21,000 opt — EDGAR
2026-06-11 Juergen Eckhardt Director Grant (A) +21,000 opt — EDGAR
2026-06-10 Matthew Wein See Remarks Sell (S) −558 $1.30 -$725 EDGAR
2026-06-10 Pamela Wapnick Chief Financial Officer Sell (S) −2,884 $1.30 -$3.7K EDGAR
2026-06-10 Jian Irish See Remarks Sell (S) −3,737 $1.30 -$4.9K EDGAR
2026-04-03 Jian Irish See Remarks Award (A) +46,000 — EDGAR
2026-04-03 Matthew Wein See Remarks Award (A) +11,000 — EDGAR
2026-04-03 Pamela Wapnick Chief Financial Officer Award (A) +24,000 — EDGAR
2026-03-09 Pamela Wapnick Chief Financial Officer Sell (S) −1,581 $1.60 -$2.5K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

MGX Insider Holdings

6 insiders · @ $0.77
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Brian C. Thomas Chief Executive Officer 2,510,960 $1.93M -$30.5K 5 2025-12-08
2 Jian Irish See Remarks 668,107 $512.7K -$26.8K 9 2026-09-10
3 Pamela Wapnick Chief Financial Officer 206,580 $158.5K -$41.2K 12 2026-09-10
4 Matthew Wein See Remarks 126,133 $96.8K -$4.7K 10 2026-09-10
5 Sarah B. Noonberg Chief Medical Officer 109,135 $83.8K -$9.2K 3 2025-06-09
6 Laurence Reid Director 20,000 $15.3K $23.4K 3 2026-09-11
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

MGX Board & Officers

As of SEC filings through Sep 11, 2026

Directors 5

Officers 4

  • Jian Irish · President and Chief Executive Officer · listed since Jun 2026
  • Pamela Wapnick · Chief Financial Officer · since Feb 8, 2024
  • Sarah B. Noonberg · Chief Medical Officer · since Feb 8, 2024
  • Matthew Wein · Title: General Counsel, Compliance Officer and Corporate Secretary · listed since Dec 2025
Changes in the last 10 years (26)
Jun 10, 2026Jian Irish listed as President and Chief Executive Officer (previously Chief Executive Officer) in SEC filings
Jun 9, 2026The company announced the departure of Brian C. Thomas from the board in an SEC filing
Dec 1, 2025Matthew Wein listed as Title: General Counsel, Compliance Officer and Corporate Secretary (previously Title: Vice President of Corporate Legal and Compliance, and Corporate Secretary) in SEC filings
Dec 1, 2025Jian Irish listed as Chief Executive Officer (previously Title: President and Chief Operating Officer) in SEC filings
Dec 1, 2025Brian C. Thomas no longer listed as Chief Executive Officer in SEC filings
Aug 11, 2025Laurence Reid became a director
Jan 27, 2025Eric Bjerkholt became a director
Feb 15, 2024Novo Holdings A/S reported in an SEC filing no longer being a 10% owner
Feb 8, 2024Willard H Dere became a director
Feb 8, 2024Simren Delaney became Title: Vice President of Intellectual Property and Legal Operations
Feb 8, 2024Simon Harnest became Title: Chief Investment Officer and Senior Vice President of Strategy
Feb 8, 2024Sebastian Bernales became a director
Feb 8, 2024Sarah B. Noonberg became Chief Medical Officer
Feb 8, 2024Pamela Wapnick became Chief Financial Officer
Feb 8, 2024Novo Holdings A/S became a 10% owner
Feb 8, 2024Matthew Wein became Title: Vice President of Corporate Legal and Compliance, and Corporate Secretary
Feb 8, 2024Luis Borges became Chief Scientific Officer
Feb 8, 2024Juergen Eckhardt became a director
Feb 8, 2024Jian Irish became a director
Feb 8, 2024Jian Irish became Title: President and Chief Operating Officer
Not reported recently (8)
  • Simon Harnest · Last reported as Title: Chief Investment Officer and Senior Vice President of Strategy in an SEC filing dated Apr 3, 2024
  • Sebastian Bernales · Last reported as a director in an SEC filing dated Apr 3, 2024
  • Luis Borges · Last reported as Chief Scientific Officer in an SEC filing dated Apr 3, 2024
  • Simren Delaney · Last reported as Title: Vice President of Intellectual Property and Legal Operations in an SEC filing dated Apr 3, 2024
  • Bayer World Investments B.V. · Last reported as a 10% owner in an SEC filing dated Feb 15, 2024
  • Bayer Healthcare LLC · Last reported as a 10% owner in an SEC filing dated Feb 15, 2024
  • Bayer US Holding LP · Last reported as a 10% owner in an SEC filing dated Feb 15, 2024
  • Aktiengesellschaft Bayer · Last reported as a 10% owner in an SEC filing dated Feb 15, 2024
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

MGX Proposed Insider Sales (Form 144)

Latest: 2025-09-11
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2025-09-11 Noonberg Sarah B. FORMER OFFICER 35,832 $68.1K 2025-09-11 MERRILL LYNCH — EDGAR
2025-07-09 Sebastian Bernales Affiliate 769,845 $1.47M 2025-07-09 J.P. Morgan Securities LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
4 ETFs hold MGX
4 shown · $1.59M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $785,891 — 2026-09-30
2 ISCF iShares International Small-Cap Equity Factor ETF iShares (BlackRock) 0.06% $402,644 $699.5M 2026-10-23
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $334,388 — 2026-09-30
4 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.01% $70,341 $1.2B 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.